trending Market Intelligence /marketintelligence/en/news-insights/trending/u_c4g4z6txeji3nn_6modg2 content esgSubNav
In This List

Anthera Pharmaceuticals gets Nasdaq noncompliance notice

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Anthera Pharmaceuticals gets Nasdaq noncompliance notice

Anthera Pharmaceuticals Inc. received a notice of noncompliance from Nasdaq Stock Market for failing to meet the minimum $1 bid price requirement.

The Hayward, Calif.-based company recently started a personnel reorganization plan to align its resources, after announcing plans to discontinue its pancreas drug Sollpura after another late stage trial failure.

Anthera, which is exploring strategic deals, said a potential deal could require the post-transaction entity to meet all of Nasdaq's initial listing criteria and complete the exchange's initial listing process.

The company may appeal Nasdaq's determination to a hearings panel within seven days from the receipt of the letter, which will stay the suspension of its securities pending the panel's decision.

Anthera, which develops and sells medicines for patients with unmet medical needs, plans to appeal the exchange's determination.